NAV

Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Lumason
Generic Name
Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)
DrugBank Accession Number
DB14105
Background

Not Available

Type
Small Molecule
Groups
Approved
Structure
Similar Structures
Weight
Average: 744.964
Monoisotopic: 744.49172986
Chemical Formula
C38H74NaO10P
Synonyms
  • 1,2-dipalmitoyl-sn-glycero-3-phosphorylglycerol sodium salt
  • L-DPPG-Na
  • R-DPPG-Na
External IDs
  • MG-6060LS
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
LumaSonSodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg)Injection, powder, lyophilized, for suspension; KitIntravenous; IntravesicalBracco Diagnostics Inc2020-01-15Not applicableUS flag
LumaSonSodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg)KitIntravenous; IntravesicalBracco Suisse SA2015-01-15Not applicableUS flag
LumasonSodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg)Injection, powder, lyophilized, for suspensionIntravenous; IntravesicalBracco Diagnostics Inc2021-04-01Not applicableUS flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
841B886EJ7
CAS number
200880-41-7
InChI Key
LDWIWSHBGAIIMV-ODZMYOIVSA-M
InChI
InChI=1S/C38H75O10P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-37(41)45-33-36(34-47-49(43,44)46-32-35(40)31-39)48-38(42)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h35-36,39-40H,3-34H2,1-2H3,(H,43,44);/q;+1/p-1/t35?,36-;/m1./s1
IUPAC Name
sodium (2R)-1-[(2,3-dihydroxypropyl phosphono)oxy]-3-(hexadecanoyloxy)propan-2-yl hexadecanoate
SMILES
[Na+].[H][C@@](COC(=O)CCCCCCCCCCCCCCC)(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC

References

General References
Not Available
ChemSpider
29763754
RxNav
1599274

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4Active Not RecruitingDiagnosticAbdominal Injuries / Falls, Accidental / Motor Vehicle Injury / Physical Abuse1
4CompletedDiagnosticAbdominal Trauma1
4CompletedDiagnosticHepatic Disease1
4CompletedOtherHepatocellular Carcinoma1
4RecruitingDiagnosticRenal Malignant Tumor1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for suspensionIntravenous; Intravesical
Injection, powder, lyophilized, for suspension; kitIntravenous; Intravesical
KitIntravenous; Intravesical
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5686060No1997-11-112017-11-11US flag
US10232061No2019-03-192038-07-06US flag
US10335502No2019-07-022038-07-06US flag
US11723869No2019-05-152039-05-15US flag

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000119 mg/mLALOGPS
logP8.32ALOGPS
logP10.94Chemaxon
logS-6.8ALOGPS
pKa (Strongest Acidic)1.89Chemaxon
pKa (Strongest Basic)-3Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area151.65 Å2Chemaxon
Rotatable Bond Count40Chemaxon
Refractivity194.19 m3·mol-1Chemaxon
Polarizability88.81 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-335.0591676
predicted
DarkChem Lite v0.1.0
[M+H]+334.3078676
predicted
DarkChem Lite v0.1.0
[M+Na]+333.6162676
predicted
DarkChem Lite v0.1.0

Drug created at June 21, 2018 16:23 / Updated at July 12, 2021 03:34